Key result
Significant CAD does not influence all-cause mortality in patients with cardiac amyloidosis.
Why the study?
The prevalence and risk factors of significant CAD in patients with CA, as well as potential outcome disparities, remain largely unexplored.
Does the presence of significant coronary artery disease impact all-cause mortality or cardiac magnetic resonance imaging features in patients with cardiac amyloidosis?
Cohort (n=255)
Does the presence of significant coronary artery disease impact all-cause mortality or cardiac magnetic resonance imaging features in patients with cardiac amyloidosis?
While obstructive CAD is common in patients with cardiac amyloidosis, it does not appear to impact overall survival, and CMR viability testing is often confounded by amyloid-specific LGE.
Obstructive CAD does not influence survival in cardiac amyloidosis; leaves open the value of routine screening and CMR viability assessment.
Background/Objectives: Cardiac amyloidosis (CA) as well as coronary artery disease (CAD) are both highly prevalent among the elderly. However, both the prevalence and risk factors associated with significant CAD among patients with CA, as well as potential outcome disparities, remain mainly unexplored. This study aimed to show the prevalence of CAD in patients with CA, as well as to assess outcomes and differences in late gadolinium enhancement (LGE) in comparison to patients with lone CA. Methods: We retrospectively assessed CA patients who underwent CAD assessment between 2013 and 2023. The primary endpoint was all-cause death. A subgroup underwent cardiac magnetic resonance imaging (CMR) with LGE assessment. Results: Of 255 consecutive patients with CA, 81 patients had significant CAD. Differences could be found with respect to age, sex, arterial hypertension, and hyperlipidemia. Significant differences in CMR features could only be found with respect to indexed left-ventricular end-diastolic volume, as well as left-ventricular mass. CAD-specific LGE was present only in 17.7% of patients with CAD, while most patients showed typical amyloid LGE, making a viability diagnosis difficult via CMR, especially in patients with end-stage CA. No differences in outcomes could be observed according to the prevalence of CAD. Conclusions: Concomitant obstructive CAD is highly prevalent among patients with CA. However, the presence of CAD does not influence patient outcomes. Furthermore, our data suggests that CAD viability testing by CMR might be complicated in patients with concomitant CA due to the high prevalence of amyloid-specific LGE.
No takes yet. Share an insight, caveat, or question.
A 2025 study conducted a cohort in Cardiac amyloidosis (n=255). Significant coronary artery disease vs. Lone cardiac amyloidosis (no significant coronary artery disease) was evaluated on All-cause death. Significant coronary artery disease was present in 81 of 255 patients with cardiac amyloidosis but did not influence all-cause death outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: